Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Haruhisa Konishi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association between miscarriage rates in modified natural ovulation cycles and hormone replacement cycles during frozen-thawed embryo transfer in three IVF JAPAN GROUP fertility clinics: a retrospective analysis

    by Haruhisa Konishi, Hiroshi Matsumoto, Sho Fujiwara, Rie Kitayama, Daisuke Kadogami, Naoharu Morimoto, Kanako Katsu, Yoshiharu Nakaoka, Aisaku Fukuda, Yoshiharu Morimoto

    Background: Optimal endometrial preparation for frozen-thawed embryo transfer (FET) remains debated owing to conflicting results regarding outcomes in modified natural ovulation cycles (NCs) versus hormone replacement cycles (HRCs). Therefore, we aimed to compare clinical pregnancy and miscarriage rates between modified NCs and HRCs in FETs. We retrospectively analyzed 9,136 clinical pregnancies by FET between January 2020 and February 2025 at three IVF JAPAN GROUP fertility clinics. Of these, 5,230 were HRCs and 3.906 were modified NCs. Clinical pregnancy was defined as the presence of a gestational sac, while miscarriage was defined as pregnancy loss before 9 weeks of gestation. Subgroup and multivariate analyses were performed, adjusting for maternal age, prior miscarriage, embryo developmental stage, and use of preimplantation genetic testing for aneuploidy. Results: Miscarriage rates were lower in the modified NC group compared with the HRC group (19.4% vs. 25.6%; P < 0.001). This reduction was also observed in high-risk subgroups, including women aged ≥ 40 and those with prior miscarriage. Multivariate analysis confirmed the association (adjusted odds ratio: 0.74; 95% confidence interval: 0.66–0.82). This trend was consistent across all facilities, despite differing NC utilization rates, and was independent of chromosomal status. Conclusions: Given that HRC remains the dominant strategy in many countries, our findings indicate that modified NC in FET may provide clinical benefits in early pregnancy outcomes.

  • Open Access

    Perspectives on Preimplantation Genetic Testing for Monogenic Disorders Among Japanese Patients With Hereditary Breast Cancer Undergoing Fertility Preservation: Insights From the First Japanese Survey

    by Haruhisa Konishi, Yoshiharu Nakaoka, Anmae Michiko, Sho Fujiwara, Rie Kitayama, Daisuke Kadogami, Naoharu Morimoto, Kanako Katsu, Satoko Fujioka, Tomoko Inoue, et al.

    Purpose: Preimplantation genetic testing for monogenic disorders ( PGT ‐M) offers BRCA variant carriers the option of preventing hereditary cancer transmission. We investigated the awareness and attitudes toward PGT ‐M among patients with breast cancer who underwent fertility preservation. Methods: A questionnaire‐based survey was administered to 264 patients with breast cancer who were eligible for oocyte or embryo cryopreservation at in vitro fertilization clinics between October 2024 and March 2025. A total of 161 valid responses were analyzed. The survey assessed BRCA testing status, PGT ‐M awareness, willingness to undergo PGT ‐M, and opinions on future availability. Results: The uptake rate of BRCA1 /2 testing was 53.4%; 14% of the respondents were variant carriers. Only 16.8% had prior awareness of PGT ‐M, and 47.8% expressed a willingness to use PGT ‐M if available. Among BRCA ‐variant carriers, 3.3% reported that they would consider PGT ‐M, and 75% believed it should be made available upon request. Overall, 68.3% supported information sharing between oncology and fertility providers. Conclusion: These findings highlight the importance of expanding reproductive options and patient awareness of PGT ‐M in the care of patients with hereditary cancer. Discussions should focus on how best to provide accurate information and enable informed reproductive choices for those at genetic risk.


  • Open Access

    Progesterone Suppresses Uterine Contraction by Reducing Odontogenic Porphyromonas gingivalis Induced Chronic Inflammation in Mice

    by Yuko Teraoka, Jun Sugimoto, Haruhisa Konishi, Hiroshi Miyoshi, Hisako Furusho, Mutsumi Miyauchi, Shunichi Kajioka, Iemasa Koh, Yoshiki Kudo

    Preterm birth is one of the most significant obstetric complications. Inflammation reportedly promotes uterine contraction and weakening of the fetal membrane, which induces preterm birth. Previous studies using animal models of lipopolysaccharide-induced acute inflammation have shown that progesterone (P4) promotes uterine quiescence. However, this effect is not fully understood in chronic inflammation. This study aimed to investigate the effects of P4 on uterine contractility and inflammation of the fetal membrane in mice infected with Porphyromonas gingivalis (P.g.), a major periodontal pathogen as a model of preterm birth caused by chronic inflammation. Mice were injected with 1 mg of P4 from day 15.5 to 17.5. P4 prolonged the mean gestation period of P.g mice from 18.3 to 20.4 days, and no reduction in the gestation period was observed. P4 treatment suppressed spontaneous uterine contractility and decreased oxytocin sensitivity. In addition, the expression of inflammatory cytokines in the fetal membrane was significantly reduced. Thus, P4 prevented preterm birth by suppressing enhanced uterine contractility induced by chronic inflammation in this model. This result describes the effects of P4 in a chronic inflammation model, which may lead to a better understanding of the efficacy of P4 in preventing preterm birth in humans.


  • Porphyromonas gingivalis, a cause of preterm birth in mice, induces an inflammatory response in human amnion mesenchymal cells but not epithelial cells

    by Haruhisa Konishi, Satoshi Urabe, Yuko Teraoka, Yoshito Morishita, Iemasa Koh, Jun Sugimoto, Shinnichi Sakamoto, Hiroshi Miyoshi, Mutsumi Miyauchi, Takashi Takata, et al.


  • Open Access

    Two Case Reports of Intravenous Leiomyomatosis with Hyaluronan Expression

    by Haruhisa Konishi, Iemasa Koh, Noriyuki Shiroma, Yukie Kidani, Satoshi Urabe, Norifumi Tanaka, Eiji Hirata, Koji Arihiro, Yoshiki Kudo

    Intravenous leiomyomatosis (IVL) is a rare benign neoplasm. Herein, we describe two cases of IVL at different levels of progression. The tumor in Case 1 was extensive, invading the right atrium after a hysterectomy for a uterine myoma. The tumor temporarily responded to hormonal treatment; however, tumor regrowth occurred. In contrast, the tumor in Case 2 extended only to the pelvic veins and was revealed preoperatively. Hysterectomy and bilateral salpingo‐oophorectomy were performed, resulting in the complete surgical resection of the tumor. In Case 2, no recurrence has been observed. Tumor samples were evaluated for hyaluronan expression using Alcian blue staining (with and without hyaluronidase digestion). The tumor in Case 1 stained strongly positive for hyaluronan while the tumor in Case 2 stained weakly positive for hyaluronan. In contrast, a large non‐IVL uterine leiomyoma (control) stained negative for hyaluronan. These results suggest a relationship between tumor hyaluronan expression and IVL progression, similar to that in other cancers.